Summary & Overview
HCPCS J9400: Ziv-aflibercept Injection, 1 mg
HCPCS Level II code J9400 denotes a 1 mg injection of ziv-aflibercept, a VEGF-targeting biologic used in ophthalmic and select systemic indications. This code matters nationally as a standardized identifier for billing and reimbursement of ziv-aflibercept administrations across outpatient settings, including ophthalmology clinics and infusion centers. Accurate use affects claim adjudication, provider revenue cycle management, and patient access to therapy.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of clinical context for ziv-aflibercept administration, typical sites of service, common billing modifiers associated with injectable biologics, and the payers included in the benchmarking set. The publication outlines what to expect in claim submission for this HCPCS Level II code and highlights where policy updates or payer-specific coverage criteria commonly influence billing outcomes.
This summary provides national-level context for coding and administrative teams, revenue cycle analysts, and clinical managers who oversee biologic injection services. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J9400 represents an injection of ziv-aflibercept, 1 mg. The service involves administering a measured dose of the anti-VEGF agent ziv-aflibercept for conditions that require intravitreal or parenteral delivery of a vascular endothelial growth factor inhibitor.
Service Type: Injection — biologic/antineoplastic agent administration
Typical Site of Service: Outpatient clinic or ambulatory surgical center, commonly in ophthalmology clinics for intravitreal injections or in outpatient infusion centers when delivered parenterally.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with neovascular (wet) age-related macular degeneration or macular edema from retinal vein occlusion who presents to an ophthalmology clinic for intravitreal pharmacotherapy. The patient has a prior diagnosis of retinal vascular disease with decreased visual acuity and macular fluid confirmed by optical coherence tomography (OCT) and a clinical exam. After informed consent and ophthalmic sterile preparation, a single-dose vial or syringe of J9400 (injection, ziv-aflibercept, 1 mg) is drawn under aseptic technique in a procedure room or minor procedure area. The ophthalmologist or qualified retinal specialist administers an intravitreal injection through the pars plana using a sterile needle after topical anesthesia and antisepsis; post-injection IOP check and brief observation follow. Typical workflow elements include pre-procedure verification of laterality and indication, medication preparation, use of topical antibiotics or povidone-iodine per clinic protocol, administration of the injection, documentation of lot number and amount administered, and a post-procedure plan for follow-up OCT and visual acuity assessment.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier applicable (placeholder) | Rarely used; not typically appended to J-codes but included when no specific modifier applies |